12th International Pediatric Renal Tumors Biology Meeting

Wednesday, June 5, 2024, 10:00 AM - Friday, June 7, 2024, 5:00 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY

This complimentary symposium at Memorial Sloan Kettering focuses on the biology and clinical translation of emerging research in pediatric renal tumors, particularly Wilms tumor, but also RCC and other rare childhood kidney tumors. The symposium will consist of didactic lectures, poster sessions, as well as focused breakout discussions, the latter being focused on pre-clinical pediatric renal tumor models and prioritizing targets and therapies for advanced Wilms tumors.

This large, but focused gathering of scientists, clinicians, and other key stakeholders, will provide significant opportunities for both learning and networking. Please see below for information on the symposium social events. We invite attendees of this symposium to join us for a variety of social events. Please be sure to RSVP for the social events during registration. We look forward to an exciting three-day event filled with ample opportunities for networking and fostering professional collaboration.

WEDNESDAY, JUNE 5, will initially begin with an educational overview of pediatric renal tumors before the scientific meeting commencement in order to provide a foundational basis for attendees with varied backgrounds. The afternoon launches the formal symposium with a focus on the renal biological processes, both physiologic and pathologic, that lead to the development of childhood kidney tumors. There will be a particular focus on renal regeneration and repair as well as advances in our understanding of clonal nephrogenesis.

Complimentary Networking Reception — At the conclusion of the symposium's activities on Wednesday, we invite attendees to a networking reception in the lobby of the Zuckerman Research Center. To confirm your participation in the reception, please select this option during your registration. Hors d'oeuvres and refreshments will be served.

THURSDAY, JUNE 6, will include discussions of advances in our understanding of the genomics, epigenomics, and proteomics of childhood kidney tumors. This will include discussion on topics such as cancer predisposition, clonal evolution, intratumoral heterogeneity, preclinical tumor models, as well as emerging technologies such as circulating tumor DNA.

Complimentary Cocktail Reception and Dinner — At the conclusion of the symposium's activities on Thursday, we invite attendees to a cocktail reception at 6:00 pm at Coco Pazzeria (1078 1st Ave), followed by a dinner at 7:00 pm at Morso (420 E 59th St). RSVP is required to attend the cocktail reception and dinner. To confirm your participation in the reception, please select this option during your registration. Space is limited, so we highly encourage early registration. 

FRIDAY, JUNE 7, will transition towards more clinically actionable investigations, consisting of talks related to immunotherapy, targeted therapies, and current and emerging clinical trials including novel study designs. There will be a particular focus on rare non-Wilms renal tumors, such as renal cell carcinoma, rhabdoid tumor, and childhood kidney sarcomas.

New York Yankees vs. Los Angeles Dodgers Baseball Game — We extend an invitation to interested attendees to join us at Yankee Stadium for a baseball game against the Los Angeles Dodgers at 7:05 pm. Kindly note that transportation will not be provided, and attendees are responsible for purchasing their tickets. If you wish to attend the game, please purchase tickets directly through our dedicated page on the NY Yankees website.

Target Audience and Symposium Location

We invite pediatric renal tumor clinicians, researchers, and students to attend this symposium on a complimentary basis. This program is set to be an exclusively in-person event at Memorial Sloan Kettering's Zuckerman Research Center (417 East 68th Street). A virtual option will not be available.

1. Discuss underlying biology of pediatric renal tumors
2. Apply new knowledge in order to advance research or clinical care of pediatric renal tumor patients

This symposium is complimentary for all attendees. Select the 'Register' tab above in order to successfully complete registration. Detailed participation instructions will be provided to registrants prior to the start of the program. We kindly request that those who register also plan to attend. If you are registered for this meeting and are unable to attend, please notify us by emailing [email protected].

Employees who are currently employed by a Pharmaceutical and Medical Device company may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities. For more information, please visit our Help 

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 18.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABP MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18.50 MOC Points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

MOC/CC points earned will be reported to the board within 45 days of the completion of the activity.

Please note Continuing Medical Education (CME) credit is not available for the Posters Sessions.

This Symposium is supported by Debbie and Kevin Bhatt Bianco Family Foundation Andrew McDonough B+ Foundation Tow Center for Developmental Oncology

Hotel Accommodations

We look forward to welcoming you to Memorial Sloan Kettering for this program. If you’ll be traveling to New York City from out of town, we recommend that you plan your overnight stays as soon as possible. To make the planning a little easier, Memorial Sloan Kettering has negotiated special rates and amenities at select hotels in Manhattan. To view the list of select hotels and additional details on each, please visit: msk.org/accommodations

Parking Information

Street parking in Manhattan is extremely limited, so you may find it more convenient to park in Memorial Sloan Kettering’s garage or in a commercial garage. For a list of parking resources around MSK, click here. Please note that MSK CME does not offer parking validation for course attendees.

Symposium Director 

Michael V. Ortiz, MD
Clinical Director, Rare Tumors Program 
Assistant Attending
Department of Pediatrics 
Memorial Sloan Kettering Cancer Center
New York, NY, USA

 

Symposium Co-Director 

Alex Kentsis, MD, PhD
Director, Tow Center for Developmental Oncology
Member 
Department of Pediatrics
Memorial Sloan Kettering Cancer Center
New York, NY, USA

 

Scientific Planning Committee 

James (Jim) Geller, MD
Director, Liver, Kidney and Retinoblastoma Programs; 
Director, Advanced Cancer Therapy Network, 
Cancer and Blood Disease Institute
Director, Pilot Translational Core Grant Program, 
Center for Clinical and Translational Science and Training
Cincinnati Children’s Hospital 
Cincinatti, OH, USA

Manfred Gessler, MD
Chair of Developmental Biochemistry 
University of Wuerzburg 
Würzburg, Germany

Andrew Hong, MD
Assistant Professor, Department of Pediatrics
Emory University School of Medicine 
Children’s Healthcare of Atlanta
Atlanta, GA, USA

Elizabeth Mullen, MD, FAAP
Program Leader, Renal Tumors
Institute Physician
Assistant Professor of Pediatrics, 
Harvard Medical School
Dana Farber Cancer Institute
Boston, MA, USA

Marry van den Heuvel-Eibrink, MD, PhD
Chair, SIOP Renal Tumor Study Group
Chair, Comprehensive Renal Cancer Center, and PI Princess Máxima Center
Utrecht, Netherlands

Arnauld Verschuur, MD, PhD
Senior Consultant, Pediatric Oncology 
Hôpital d'Enfants de La Timone 
Marseille, France

 

Keynote Presenters 

John Anderson, PhD
Consultant Paediatric Oncologist
University College London
London, England 

Sam Behjati, MA, BMBCh, PhD, MRCPCH
Group Leader & Wellcome Senior Research Fellow
Wellcome Trust Sanger Institute 
Hixton, England

Brian D. Crompton, MD
Research Co-Director, Solid Tumor Center
Dana-Farber Cancer Institute  
Boston, MA, USA

Benjamin Dekel, MD, PhD
Chief, Pediatric Nephrology
Director, Pediatric Stem Cell Research Institute
Sheba Medical Center 
Ramat Gan, Israel

Elizabeth (Lisa) Petri Henske, MD
Director of the Center for LAM Research and Clinical Care
Brigham and Women's Hospital 
Boston, MA, USA

Roland P. Kuiper, PhD
Professor of Molecular Genetics of Hereditary Cancer in Children, Department of Genetics, 
University Medical Center Utrecht, University of Utrecht
Group Leader at the Princess Máxima Center for Pediatric Oncology
Utrecht, Netherlands

 

Guest Speaker 

Conrad Fernandez, MD
Professor Emeritus
Dalhousie University 
Halifax, Nova Scotia, Canada

 

Breakout Session Facilitators 

Jesper Sune Brok, MD, PhD
Consultant
Department of Pediatric Oncology and Hematology, Rigshospitalet
Copenhagen University Hospital
Copenhagen, Denmark

Filemon Dela Cruz, MD
Assistant Attending
Department of Pediatrics 
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Peter Hohenstein, PhD
Associate Professor 
Department of Human Genetics and head Transgenic Facility Leiden
Leiden University Medical Center
Leiden, The Netherlands

Andrew Jackson Murphy, MD
Associate Member, Department of Surgery
St. Jude Children’s Research Hospital
Memphis, TN, USA

Daniela Perotti, PhD
Staff Scientist
Experimental Oncology Department
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Milan, Italy

Amy Walz, MD
Clinical Practice Director, Center for Cancer & Blood Disorders, 
Ann & Robert H. Lurie Children’s Hospital of Chicago
Assistant Professor of Pediatrics, Northwestern Univ. Feinberg School of Medicine
Ann & Robert H. Lurie Children's Hospital of Chicago, Department of Pediatrics
Division of Hematology, Oncology, Neuro-Oncology, & Stem Cell Transplant  
Chicago, IL, USA

Jenny Wegert, PhD
Developmental Biochemistry 
University of Wuerzburg 
Wuerzburg, Germany

 

Oral Presenters

Natalie Andersson, MD, PhD Student
Lund University
Lund, Sweden 

Kaushal Asrani, MBBS, PhD
Johns Hopkins School of Medicine
Baltimore, MD, USA

Jack Brzezinski, MD
The Hospital for Sick Children
Toronto, Canada

Martha Donoghue, MD
FDA Oncology Center of Excellence
Silver Spring, MD, USA

Keri Drake, MD
University of Texas Southwestern Medical Center
Dallas, TX, USA 

Yaniv Kazansky, PhD
Cornell Medical School 
New York, NY, USA

Tobias Karakach, PhD
Dalhousie University
Halifax, Canada

Patrick Kemmeren, PhD
Princess Máxima Center for Pediatric Oncology 
Utrecht, The Netherlands

Prathyusha Konda, PhD
Dana-Farber Cancer Institute
Boston, MA, USA

Sophie van Peer, MD, PhD Student
Princess Máxima Center for Pediatric Oncology 
Utrecht, The Netherlands

Prahalathan Pichavaram, PhD
St. Jude Children's Hospital
Memphis, TN, USA

Damon Reed, MD
Memorial Sloan Kettering Cancer Center
New York, NY, USA

David Steffin, MD
Texas Children's Hospital
Houston, TX, USA

Lola Takhirov, BA, PhD Student
University of Southern California
Los Angeles, CA, USA

Patricia D. B. Tiburcio, PhD
University of Texas Southwestern Medical Center
Dallas, TX, USA

Srinivas Viswanathan, MD, PhD
Dana-Farber Cancer Institute
Boston, MA, USA

Liling Wan, PhD
Univeristy of Pennsylvania
Philadelphia, PA, USA

 

Poster Presenters (Non-Accredited Session)

Reem Al-Saadi, BSc
University College London
London, United Kingdom

Teaghan Frauley, BS
University of Toronto
Toronto, Canada 

Jayne Hehir-Kwa, PhD
Princess Máxima Center
Utrecht, Netherlands 

Alissa Groisser, MD
Children's National Hospital 
Washington, D.C., USA

Nicole Ludwig, PhD
Saarland University
Saarbrücken, Germany

Marina Parisi Dutra, MD
Hospital for Sick Children, 
University of Toronto
Toronto, Canada  

Julia Sprokkerieft, PhD Student
Princess Máxima Center
Utrecht, Netherlands

Robyn Spoon, MA
Elevate Childhood Cancer Research and Advocacy 
Columbus, IN, USA

Elisabeth (Lisa) Tracy, MD
Duke University
Durham, NC, USA

Sophie Van Peer, MD, PhD Student
Princess Máxima Center
Utrecht, Netherlands

Cary Weiss, MD, PhD
Dana Farber Cancer Institute
Boston, MA, USA

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.